• GlaxoSmithKline Receives FDA Approval to use AES CHEMUNEX’s ChemScan RDI for Real-Time In- Process Monitoring

Laboratory Products

GlaxoSmithKline Receives FDA Approval to use AES CHEMUNEX’s ChemScan RDI for Real-Time In- Process Monitoring

GlaxoSmithKline Parma (Italy) manufacturing site has received inspection and formal approval from the FDA to use the ChemScan RDI scanning cytometer from AES CHEMUNEX, as a part of the rapid microbiological inprocess monitoring of a non-sterile nasal spray product. Rapid monitoring of the manufacturing process using more sensitive tests allows accurate prediction of product quality; thus eliminating the need of final product testing to release the prescription product to the market.

The recent work with the ChemScan RDI has delivered confidence in the speed and high sensitivity of the system to deliver accurate and early counts for the control of surfaces and product bulk solutions.

In addition to pharmaceutical waters testing, the sensitivity of the ChemScan RDI is used to deliver ‘real time’ microbiological process controls for product bulk monitoring using bioburden application and surface monitoring using ChemSwab application.

The ChemScan RDI laser scanning cytometer delivers counts of viable microorganisms within 3 hours after sampling, with sensitivity down to a single cell; without the requirement for a growth phase while the standard
growth plate method typically takes 48 to 72 hours (TSA) or 5 to 14 days (R2A) to deliver counts of culturable organisms. Such growth-based methods do not allow early confirmation that the water system, the product bulks, and the surfaces in controlled production area are within approved microbiological limits, any response being retrospective to the production process.

ChemScan RDI tests for rapid environmental monitoring and in-process measurements as part of a continuous quality assurance programme enable constant monitoring, evaluation and adjustment of the process
reducing the expensive risk of contaminated product.

Furthermore, the technology being non-destructive, GSK demonstrated, during FDA audit, that the ChemScan RDI protocol enables micro-organism recovery on traditional culture media for identification purpose.

More information on www.aeschemunex.com


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

View all events